Pancreatic Cancer Research

ResearcherJiangsu UniversityNo recent work listed

Jianping Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2789-7244; OpenAlex author ID A5103156817. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2012: 1 paper · 2013: 4 papers · 2014: 6 papers · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 20

  1. [Corrigendum] Expression and prognostic significance of TRPV6 in the development and progression of pancreatic cancer. Co-author DOI 10.3892/or.2022.8395↗
  2. Calreticulin promotes EMT in pancreatic cancer via mediating Ca2+ dependent acute and chronic endoplasmic reticulum stress. Co-author DOI 10.1186/s13046-020-01702-y↗
  3. C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activating ERK signaling pathway. Co-author DOI 10.1007/s11010-018-3455-0↗
  4. Serine/arginine protein-specific kinase 2 promotes the development and progression of pancreatic cancer by downregulating Numb and p53. Co-author DOI 10.1111/febs.14778↗
  5. Silencing Tspan1 inhibits migration and invasion, and induces the apoptosis of human pancreatic cancer cells. Co-author DOI 10.3892/mmr.2018.9331↗
  6. Expression and prognostic significance of TRPV6 in the development and progression of pancreatic cancer. Co-author DOI 10.3892/or.2018.6216↗
  7. Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. Co-author DOI 10.1038/cddis.2017.547↗
  8. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer. Last author DOI 10.1096/fj.201601240r↗
  9. MUC4-promoted neural invasion is mediated by the axon guidance factor Netrin-1 in PDAC. Co-author DOI 10.18632/oncotarget.5668↗
  10. Overexpression of calreticulin contributes to the development and progression of pancreatic cancer. Co-author DOI 10.1002/jcp.24519↗
  11. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer. Co-author DOI 10.1111/his.12273↗
  12. [Expression and significance of leukemia inhibitory factor in human pancreatic cancer]. First author PMID 24721346↗
  13. [The role of Gli1 in the invasion and migration of pancreatic cancer cells]. Co-author PMID 25262609↗
  14. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer]. Co-author PMID 25410780↗
  15. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma]. Co-author PMID 25573220↗
  16. Down regulation of CAII is associated with tumor differentiation and poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/jso.23282↗
  17. Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer. Co-author DOI 10.1007/s00441-013-1679-6↗
  18. [Clinicopathological significance of the expression of calreticulin in human pancreatic cancer]. Co-author PMID 23578430↗
  19. [Correlation between Gli1 expression and clinicopathological significance in human pancreatic cancer]. Co-author PMID 24433772↗
  20. [Clinicopathological significance of the expression of carbonic anhydrase I and II in human pancreatic cancer]. Co-author PMID 23327700↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weiwei Sheng · 19 shared papers, 2012–2022 · strength 1.34
  2. Ming Dong · 14 shared papers, 2012–2022 · strength 1.11
  3. Qi Dong · 8 shared papers, 2013–2014 · strength 0.37
  4. Guosen Wang · 3 shared papers, 2017–2020 · strength 0.29
  5. Song He · 1 shared paper, 2022 · strength 0.19
  6. Wei Gao · 1 shared paper, 2022 · strength 0.19
  7. Qingfeng Liu · 4 shared papers, 2013–2014 · strength 0.18
  8. Song He · 2 shared papers, 2017–2018 · strength 0.17
  9. Feng Li · 3 shared papers, 2013–2014 · strength 0.14
  10. Gang Shi · 2 shared papers, 2014–2018 · strength 0.12
  11. Xin Li · 1 shared paper, 2019 · strength 0.11
  12. Yuji Li · 2 shared papers, 2012–2017 · strength 0.11
  13. Rongxian Cao · 1 shared paper, 2020 · strength 0.11
  14. Jian Hua Sun · 1 shared paper, 2020 · strength 0.11
  15. Chao Jia · 1 shared paper, 2020 · strength 0.11
  16. Wei Gao · 1 shared paper, 2018 · strength 0.10
  17. Qingfeng Liu · 2 shared papers, 2014 · strength 0.09
  18. Xin Li · 2 shared papers, 2013 · strength 0.09
  19. Kewei Wang · 1 shared paper, 2017 · strength 0.07
  20. Yunwei Li · 1 shared paper, 2017 · strength 0.07
  21. Jiaxun Tian · 1 shared paper, 2018 · strength 0.07
  22. Xiaobo Zhang · 1 shared paper, 2018 · strength 0.07
  23. Shuangning Ding · 1 shared paper, 2017 · strength 0.07
  24. Fei Peng · 1 shared paper, 2014 · strength 0.06
  25. Wei Sun · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.